Editorial:<scp>HBsAg</scp>seroclearance after pegylated interferon treatment—The beginning of the end. Authors' reply-Reference-Cited by-同舟云学术

Editorial:HBsAgseroclearance after pegylated interferon treatment—The beginning of the end. Authors' reply

Published:2023-10-26 Issue:10 Volume:58 Page:1105-1106
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Gao Na¹²³^ORCID,Guan Guiwen⁴^ORCID,Zhao Qiyi¹²³^ORCID,Gao Zhiliang¹²³^ORCID

Affiliation:

1. Department of Infectious Diseases Third Affiliated Hospital of Sun Yat‐Sen University Guangzhou Guangdong China

2. Guangdong Key Laboratory of Liver Disease Research The Third Affiliated Hospital of Sun Yat‐Sen University Guangzhou China

3. Key Laboratory of Tropical Disease Control (Sun Yat‐Sen University), Ministry of Education Guangzhou Guangdong China

4. Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences Peking University Beijing China

Abstract

LINKED CONTENTThis article is linked to Gao et al papers. To view these articles, visithttps://doi.org/10.1111/apt.17670andhttps://doi.org/10.1111/apt.17690

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.17710

Reference10 articles.

1. Editorial: HBsAg seroclearance after pegylated interferon treatment—the beginning of the end;Mak L‐Y;Aliment Pharmacol Ther,2023

2. Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens

3. Reduction in intrahepatic cccDNA and integration of HBV in chronic hepatitis B patients with a functional cure;Gan W;J Clin Transl Hepatol,2023

4. Serum HBV RNA is a Potential Predictor of Hepatitis B Surface Antigen Reversion

5. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB